Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Roche May Be Right" In Not Taking To Generic Drugs - IMS Health; "Innovation Surge" From 2016 Will Help Big Pharma

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Global pharmaceutical companies - traditionally originators of blockbuster drugs - may not be expected to become part of a "long list of generic players" even by 2020, according to leading industry data and consulting firm IMS Health. However, experts believe MNCs will pursue specific areas where their skill sets can offer competitive advantages

You may also be interested in...



Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 1 of 2)

Although Deutsche Bank agrees with most analysts that emerging markets are an important growth driver for big pharma, the brokerage believes that many observers under appreciate the challenges ahead, and that familiar strategies such as branded generics and local acquisitions may be short-term plays that won't necessarily translate to long-term success in rapidly changing markets like Brazil, Russia, India and China

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 1 of 2)

Although Deutsche Bank agrees with most analysts that emerging markets are an important growth driver for big pharma, the brokerage believes that many observers under appreciate the challenges ahead, and that familiar strategies such as branded generics and local acquisitions may be short-term plays that won't necessarily translate to long-term success in rapidly changing markets like Brazil, Russia, India and China

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets?

Pricing pressure will increase over time in emerging markets, hitting the bottom line of multinationals, particularly those with high exposure to branded generics, Deutsche Bank predicts.

Related Content

UsernamePublicRestriction

Register

SC073789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel